Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin
- 31 August 2004
- journal article
- clinical trial
- Published by Elsevier BV in Lung Cancer
- Vol. 45 (2), 227-236
- https://doi.org/10.1016/j.lungcan.2004.01.011
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trialLung Cancer, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A ReviewJournal of Clinical Oncology, 2000
- Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?Lung Cancer, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Chemotherapy and Survival in Non-Small Cell Lung CancerChest, 1994
- Chemotherapy and Survival in Non-Small Cell Lung CancerChest, 1991
- Reporting results of cancer treatmentCancer, 1981
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960